Advocacy Wealth Management Services’s Array Biopharma Inc ARRY Stock Holding History

Advocacy Wealth Management Services’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	$6K	Buy	+1,000	New	+$5.94K	0.02%	246

Other funds holding ARRY

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Advocacy Wealth Management Services's ARRY Position: Q3 2013 in Review

Advocacy Wealth Management Services opened a new position in Array Biopharma Inc (ARRY) in Q3 2013: 1,000 shares worth $6K. The stake represents 0.02% of the portfolio and ranks #246 among its holdings.

134 funds tracked by Wall St. Rank hold ARRY as of Q3 2013.

Advocacy Wealth Management Services held 1,000 shares of Array Biopharma Inc worth $6K as of Q3 2013.
Array Biopharma Inc was a new Advocacy Wealth Management Services position in Q3 2013.
Array Biopharma Inc made up 0.02% of Advocacy Wealth Management Services's portfolio in Q3 2013, its #246 holding.
134 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2013.

Based on Advocacy Wealth Management Services's 13F filing for Q3 2013, filed 14 Nov 2013.